Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

NCT05596097 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

DRUG: Zanubrutinib

Sponsor

LanZhou University

Collaborators

[object Object]